Quince Therapeutics, Inc. (QNCX) vs Traws Pharma, Inc. (TRAW)

A side-by-side comparison of Quince Therapeutics, Inc. and Traws Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — QNCX vs TRAW

growth of $100 · dividends reinvested · last 7y
QNCX -99.6% (-54.1%/yr)TRAW -100.0% (-68.0%/yr)QNCX compounded faster over this window
Log scale — wide-divergence pair
001101001kStart $100202120232025$0$0
QNCX TRAW

QNCX vs TRAW: by the numbers

  • •TRAW is the larger company ($8M vs $8M market cap).
  • •TRAW is profitable (328.67% net margin) while QNCX runs a net loss (0.00%).

Metrics side by side

Profitability

MetricQNCXTRAW
Gross margin0.00%100.00%
Operating margin0.00%-640.68%
Net margin0.00%328.67%
ROE-85.24%N/A
ROIC-107.08%N/A

Growth (annualized)

MetricQNCXTRAW
Revenue CAGR (5Y)N/A64.60%
Total return CAGR (5Y)-72.96%-64.14%

Frequently asked

Is QNCX or TRAW more profitable?
TRAW runs the higher net margin — QNCX at 0.00% versus TRAW at 328.67%.
How have QNCX and TRAW total returns compared?
Over the past 5 years, QNCX delivered -72.96% and TRAW delivered -64.14% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.